

Malaria vaccines as prevention strategies: for more studies on community perception

Camila H. Coelho

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville

Date Received: 09-Jan-2018
Revisions Received: 19-Feb-2018
Date Accepted: 19-Mar-2018

Correspondence: Camila H. Coelho
(camila.coelho@nih.gov)

<http://dx.doi.org/10.4314/mmj.v30i3>

Proper implementation of efficient malaria control tools is essential to program success and public health. Millions of lives are affected annually due to the disease, and despite widespread treatment and prevention efforts, malaria remains a scourge on the African continent¹. Important strategies to prevent the disease involve (1) use of vector control measures, such as insecticide-treated nets (ITN) or indoor residual spray (IRS) and (2) the development of vaccines that protect humans or reduce transmission. Successful implementation of these strategies can result in significant malaria reduction², but this requires careful consideration of the communities in which these strategies are implemented. A deep understanding of community perceptions and expectations is fundamental to crafting an effective malaria reduction strategy.

In his paper published in the Malawi Medical Journal, Parker et al. addresses important questions regarding the assessment of community perception in malaria-endemic areas. The authors discussed the practical limitations of bed net usage based on common behaviors that perhaps were not considered during program design; for example, in the evening, many community members chat with neighbors outside prior to going to bed, and despite proper bed net usage, they can still contract malaria. This may foster the perception that ITNs are ineffective. Further, understanding community perceptions will not only identify challenges and limitations, but may also reveal possible improvements, solutions, and alternative strategies. One common perception is that insect repellents could be provided for routine use by the community, and not just by tourists. In addition, engaged community members are ultimately responsible for social mobilization, increasing public awareness, and education on prevention efforts.

While several studies have evaluated community perception on vector control, a strategy successfully implemented in the field, few have analyzed the acceptability of malaria vaccines, a much newer approach for malaria control and eradication. Many types of malaria vaccines are currently under development and several are being tested in clinical trials³, but some questions related to malaria vaccines need evaluation. Among the three countries selected for pilot implementation of RTS,S vaccine, Ghana and Kenya have published studies assessing community perceptions of malaria vaccines^{4,5} and studies in Malawi will be similarly important.

Intramuscular delivery of malaria vaccines is generally well-accepted⁶, but the protection achieved by this route is relatively modest and short-lived⁷. In contrast, intravenous

delivery may confer a higher level of protection^{8,9} but we still do not know how communities view the implementation of an intravenous vaccine. Several questions need to be addressed in future studies of malaria vaccines: can the community understand, accept, and promote the idea of receiving a whole organism vaccine? What do people in endemic areas think about vaccines made with genetically attenuated parasites? Are they receptive to the idea of receiving a transmission-blocking vaccine that can protect the community, but not themselves directly? Listening to the community can improve the strategies already implemented or in development. Let's hear what they have to say.

Acknowledgment

Camila Coelho is supported by the Intramural Research Program of the National Institutes of Health.

References

1. WHO. World Malaria Report 2017. <http://www.who.int/malaria/publications/world-malaria-report-2017/report/en/>. 2017.
2. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. *Vaccine*. 2015;33 Suppl 4:D13-23; doi: 10.1016/j.vaccine.2015.07.091.
3. Coelho C, Doritchamou J, Zaidi I, Duffy PE. Advances in malaria vaccine development: Report from the 2017 Malaria Vaccine Symposium. *NPJ Vaccines*. 2017;2:34. doi: 10.1038/s41541-017-0035-3.4.
4. Febir LG, Asante KP, Dzorgbo DB, Senah KA, Letsa TS, Owusu-Agyei S. Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. *Malar J*. 2013;12:156; doi: 10.1186/1475-2875-12-156.
5. Ojaka D, Yamo E, Collymore Y, Ba-Nguz A, Bingham A. Perceptions of malaria and vaccines in Kenya. *Hum Vaccin*. 2011;7 10:1096-9; doi: 10.4161/hv.7.10.17496.
6. WHO. Malaria vaccine: WHO position paper, January 2016 - Recommendations. *Vaccine*. 2017; doi: 10.1016/j.vaccine.2016.10.047.
7. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. *PLoS Med*. 2014;11 7:e1001685; doi: 10.1371/journal.pmed.1001685.
8. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against *Plasmodium falciparum* malaria by PfSPZ Vaccine. *JCI Insight*. 2017;2 1:e89154; doi: 10.1172/jci.insight.89154.
9. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against *Plasmodium falciparum* via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. *Lancet Infect Dis*. 2017;17(5):498-509. doi: 10.1016/S1473-3099(17)30104-4.